A New Family of Antibodies
Kenjockety Biotechnology’s approach to targeting Efflux Pumps (EPs) is fundamentally different from prior efforts. Our BASETM Platform pairs the targets of both an Efflux Pump and a Tumor Associated Antigen (TAA) to create multi-modal bispecific antibodies (BsAbs) that are highly specific to cancer cells.
BASE Platform: Bispecific Antibodies Specific to Efflux Pumps
Our BASE Platform generates multi-modal BsAb product candidates, ready for IND enabling studies. Our EP mAb discovery program has established a library of functional antibodies to multiple EPs. Our BsAb engineering expertise and use of common light chains provide a robust format to create a wide array of constructs. We have developed proprietary methods to optimize molecules and select product candidates to be advanced to IND enabling studies.
Targeting EPs and TAAs creates expansive pipeline
- EPs are known to play a central role in drug resistance
- > 200 mAbs targeting TAAs in clinical development for cancer indications
- > 30 mAbs targeting TAAs with marketing approval for patients with cancer
- Pairing various EPs and TAAs represents hundreds of potential BsAb therapeutics
| Kenjockety Prioritized Efflux Pumps |
|---|
| ABCB1 [Multidrug Resistance Protein (MDR1), P-glycoprotein (PgP)] |
| ABCG2 [Breast Cancer Resistance Protein (BCRP)] |
| ABCC1 [Multidrug Resistance Protein (MRP1)] |
| ABCC4 [Human Organic Anion Transporter (MRP4)] |
| Potential Tumor Associated Antigen (TAA) Targets | ||
|---|---|---|
| CD47 | HER2 | EGFR |
| PD-L1 | CD20 | LIV1 |
| CD44 | CD33 | TIM-3 |
| LAG-3 | OX40 | cMET |
| CD19 | AXL | CD133 |
| LY6E | LRRC15 | Nectin4 |
| gpNMB | Mesothelin | CD73 |
| CD70 | ENPP3 | CD30 |
| CD66e | Fuc-GM1 | etc. |
